Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome

NCT: NCT04647656 · RECRUITING

NCT IDNCT04647656
StatusRECRUITING
Start Date2023-06-01
Completion2027-12-31

Brief Summary

Post-COVID-19 syndrome is an assembly of symptoms, following an infection with Coronavirus disease 2019 (COVID-19). The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain and more. This long-term sequela can last for months after recovering from the virus, and no treatment is known to date. The aim of this study is to compare the effect of HBOT vs. Sham on post COVID-19 syndrome

Frequently Asked Questions

What is Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome?

Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome is a clinical trial registered under NCT04647656. Current status: RECRUITING.

What is the status of NCT04647656?

The current status of NCT04647656 (Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome) is: RECRUITING.

When did Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome start?

Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome started on 2023-06-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.